Recent Quotes (30 days)

You have no recent quotes
chg | %

Cyprotex plc  

(Public, LON:CRX)   Watch this stock  
Find more results forCRX
- Close
LON real-time data - Disclaimer
Currency in
Range     -
52 week 84.00 - 160.50
Open     -
Vol / Avg. 0.00/22,515.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -0.15
Shares 22.51M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 33.85% -41.69%
Operating margin 17.13% 12.66%
EBITD margin - 20.87%
Return on average assets 36.87% -45.66%
Return on average equity - -
Employees 121 -
CDP Score - -


24, Mereside, Alderley Park
United Kingdom - Map
+44-1625-505100 (Phone)
+44-1625-505199 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Cyprotex PLC is a holding company. The Company and its subsidiaries are engaged in the provision of in vitro and in silico Absorption, Distribution, Metabolism, Excretion, Toxicity (ADMET) and Pharmacokinetic (PK) information to the pharmaceutical and biotechnology industries. It offers a range of different services in the areas of ADME-PK, in vitro toxicology, biosciences, in silico prediction, in vitro skin and ocular testing, endocrine disruption and physicochemical profiling. Its in vitro ADME and drug metabolism and pharmacokinetics (DMPK) services include in vitro metabolism, in vitro permeability and transporters, solubility and physicochemical properties, in vitro protein binding and PK and bioanalysis. It operates mainly in North America, Mainland Europe and the United Kingdom. It serves pharmaceutical, biotech, cosmetics, personal care, household products, chemical, agrochemical and tobacco markets. Its subsidiaries include Cyprotex Discovery Limited and Cyprotex US, LLC.